Patents by Inventor Magdalena Plebanski
Magdalena Plebanski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11573234Abstract: The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.Type: GrantFiled: May 18, 2018Date of Patent: February 7, 2023Assignee: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGYInventors: Magdalena Plebanski, Mutsa Tatenda Madondo
-
Publication number: 20200158733Abstract: The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.Type: ApplicationFiled: May 18, 2018Publication date: May 21, 2020Applicant: Royal Melbourne Institute of TechnologyInventors: Magdalena PLEBANSKI, Mutsa Tatenda MADONDO
-
Patent number: 8846026Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: GrantFiled: October 27, 2011Date of Patent: September 30, 2014Assignee: PX Biosolutions Pty LtdInventor: Magdalena Plebanski
-
Patent number: 8287877Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: GrantFiled: October 21, 2009Date of Patent: October 16, 2012Assignee: PX Biosolutions Pty Ltd.Inventor: Magdalena Plebanski
-
Publication number: 20120082725Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: October 27, 2011Publication date: April 5, 2012Applicant: PX Biosolutions Pty LTDInventor: Magdalena Plebanski
-
Publication number: 20110159034Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: November 5, 2010Publication date: June 30, 2011Inventors: Andrew McMICHAEL, Adrian V.S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20100136043Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: October 21, 2009Publication date: June 3, 2010Applicant: AUSTIN RESEARCH INSTITUTEInventor: Magdalena Plebanski
-
Publication number: 20100119551Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: June 19, 2009Publication date: May 13, 2010Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20090324632Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: May 15, 2009Publication date: December 31, 2009Applicant: Oxxon Therapeutics Ltd.Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20090191237Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: August 4, 2008Publication date: July 30, 2009Applicant: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Patent number: 7514087Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: GrantFiled: April 28, 2004Date of Patent: April 7, 2009Assignee: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Patent number: 7407661Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: GrantFiled: April 28, 2004Date of Patent: August 5, 2008Assignee: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040213799Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: October 16, 2003Publication date: October 28, 2004Applicant: Oxxon Pharmaccines LimitedInventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040197349Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: April 28, 2004Publication date: October 7, 2004Applicant: Oxxon Therapeutics Ltd.Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040191272Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: April 28, 2004Publication date: September 30, 2004Applicant: Oxxon Therapeutics Ltd.Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040175365Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: April 28, 2004Publication date: September 9, 2004Applicant: Oxxon Therapeutics Ltd.Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040131594Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: September 2, 2003Publication date: July 8, 2004Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20040014708Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: June 30, 2003Publication date: January 22, 2004Inventor: Magdalena Plebanski
-
Patent number: 6663871Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: GrantFiled: December 9, 1999Date of Patent: December 16, 2003Assignee: Oxxon Pharmaccines Ltd.Inventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20020136733Abstract: 8-11-Mer peptides are identified, from four Plasmodium falciparum antigens, circumsporozoite protein, thrombospondin-related anonymous protein, spirozoite hepatocyte binding antigen and liver-stage antigen-1, as actual or potential cytotoxic T lymphocyte epitopes for human leucocyte antigen class I molecules HLA-A2, HLA-B8, HA-B7 and HLA-B17. Vaccines for immunization against malaria contain these peptides or oligonucleotides coding for them. A method of inducing primary cytotoxic T lymphocyte responses to a chosen antigen or microorganism comprises incubating lymphocytes ex vivo with the chosen antigen or microorganism in the presence of keyhole limpet haemocyanin.Type: ApplicationFiled: January 11, 2002Publication date: September 26, 2002Inventors: Adrian Vivian Sinton Hill, Michael Aidoo, Catherine Elizabeth Margaret Allsopp, Ajit Lalvani, Magdalena Plebanski, Hilton Carter Whittle